Citigroup Inc Oramed Pharmaceuticals Inc. Transaction History

Citigroup Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$2.51 - $3.55 $10,107 - $14,295	4,027 Added 10.75%	41,471 $108,000
Q2 2023 Aug 10, 2023	BUY	$2.12 - $4.47 $26,262 - $55,374	12,388 Added 49.44%	37,444 $134,000
Q1 2023 May 11, 2023	SELL	$1.93 - $13.1 $78,809 - $534,925	-40,834 Reduced 61.97%	25,056 $54,000
Q4 2022 Feb 09, 2023	BUY	$5.88 - $12.03 $207,246 - $424,009	35,246 Added 115.02%	65,890 $792,000
Q3 2022 Nov 10, 2022	BUY	$4.6 - $9.91 $124,480 - $268,174	27,061 Added 755.26%	30,644 $199,000
Q2 2022 Aug 10, 2022	BUY	$3.72 - $9.0 $4,233 - $10,242	1,138 Added 46.54%	3,583 $16,000
Q1 2022 May 12, 2022	SELL	$8.19 - $13.89 $47,821 - $81,103	-5,839 Reduced 70.49%	2,445 $21,000
Q4 2021 Feb 10, 2022	BUY	$12.98 - $29.75 $62,810 - $143,960	4,839 Added 140.46%	8,284 $118,000
Q3 2021 Nov 10, 2021	BUY	$12.13 - $23.82 $41,787 - $82,059	3,445 New	3,445 $76,000

7.4M

2.1K

Ticker ORMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,100
Market Cap $92M
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.